The USFDA recently is-sued a guideline titled product Launch Notification under Section 506I. The guideline instructs companies to let the USFDA know if a product is not launched even after 180 days of getting approval. USFDA felt the need to issue this guideline on product launch since data shows that only about 40 per cent of generic products are getting launched after USFDA approval within a year. This means about 60 per cent of products are not getting launched after USFDA approval even after a year. The data also shows that even after five years about 30 per cent of products are not getting launched. Pharma companies spend a lot of money on development, bio studies, filing of product and pay GDUFA fees. Then, why are the products not launched even after approval? The answer is that there are way too many competitors marketing the same product thereby reducing the scope of marketing or the cost of the product is prohibitive to selling the product at a competitive price.
Essentially two developments have happened in the last couple of years:
1. The USFDA stepped up approval of products by introducing GDUFA and inducted a lot of new inspectors/reviewers to clear the backlogs of approval. From a backlog of more than 36 months once, one can expect approval of new product now in 12-14 months if the quality of filing and data is acceptable. This helped in more generic products getting approval, throwing the US market into intense competition.
2. The market consolidated in the US and from about 10-12 buyers, today about 90 per cent of buying are controlled effectively by three buyers only, namely – Red Oak, Walgreen- Boots Alliance & McKesson. This means the buyers have now very high bargaining power bringing price pressure on marketed products. It is now a win-win situation for both, the government and consumers in the US.
Esta historia es de la edición October 2020 de Express Pharma.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición October 2020 de Express Pharma.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor? Conectar
MAKING SUSTAINABILITY SUSTAINABLE
Driven by stringent regulations, rising investor expectations, consumer demand, and operational considerations, MSME pharma companies need to carefully balance their sustainability goals with financial viability
New energy recovery system for tablet coaters
Upto 50 per cent less steam energy consumption
The future of pharma logistics: Trends, challenges, and opportunities
Nikhil Agarwal, President, CJ Darcl Logistics explains that the future of pharma logistics is a thrilling frontier shaped by technological advancements, regulatory challenges, and the imperative of sustainability. As the industry transforms, logistics providers must embrace innovative solutions and adapt to shifting demands
Achieving Aatmanirbharta In APIs Are We On The Right Track?
As India gears up to celebrate its 75th Independence Day, self reliance in APIs remains a key goal for the pharma sector. AatmaNirbharta will be crucial for the sector as it continues to protect the country from the existing and emerging health threats
Yokogawa launches OpreX Data Model Broker
A plant data transformation platform, OpreX automatically verifies discrepancies and inconsistencies in data to improve efficiency in plant construction and operation
Understanding the nuances of generics injectables
At a webinar, explaining the West Pharma's AccelTRA Components Program, industry experts explained why the use of glass vials and stoppers as primary container closure systems (CCS) has become crucial
Trending in nutraceuticals: Science meets sustainability
Zeljko Pockaj, Vice President, Global Pharmaceutical Industry, mentions the key trends that are believed to drive innovations and formulations for nutraceuticals’ development around the globe
The growth of e-pharmacies in India
Rahul Nath Choudhury, Research fellow, ICWA, explains what motivates people in the pharma industry to invest into e-pharmacies, along with various other growth factors associated with these
Xylitol and Maltitol: Low-calorie sugar alternatives
Polyols like Xylitol and Maltitol offer important health benefits. Unlike general sugar-free sweeteners, these do not have any bitter-after taste
Single-use TC gaskets and their importance
Depending on the application, gaskets are manufactured by different types of Material of Construction (MOC) such as Silicone, EPDM, Viton (FKM), Nitrile, Neoprene, PTFE, etc.